Maternal RSV vaccination cuts infant hospitalization risk by over 80%, major study finds

A major clinical study demonstrates that vaccinating pregnant women against respiratory syncytial virus (RSV) reduces infant hospitalization from RSV-related lower respiratory tract infections by over 80%. RSV is a leading cause of infant hospitalization worldwide, causing severe bronchiolitis and pneumonia in young children. Early RSV infection is linked to long-term respiratory complications including recurrent wheeze, asthma development, and impaired lung function. This maternal vaccination strategy offers significant protection for vulnerable infants during their first months of life, when RSV poses the greatest risk.